AYVAKIT® avapritinib | tablets

Join us for a promotional education speaker program about AYVAKIT

AYVAKIT® (avapritinib) is an FDA-approved treatment for adults with Advanced Systemic Mastocytosis (Advanced SM). Limitations of Use: AYVAKIT (avapritinib) is not recommended for the treatment of patients with AdvSM with platelet counts of <50 x 10^9/L.

During this program, you will hear from an expert who will discuss the following topics:

- Introduction to Advanced Systemic Mastocytosis (Advanced SM)
- Overview of AYVAKIT Prescribing Information, including clinical trial data, safety information, and dosing recommendations
- Hypothetical patient cases based on clinical trial experience

AYVAKIT: The only targeted therapy FDA-approved for adults with Advanced SM designed for potent and selective inhibition of KIT D816V[1]

Presented (on behalf of Blueprint Medicines) by:

Christopher Maisel, MD

Texas Oncology, PA

Tuesday, November 01, 2022, 06:00 PM CDT

Capital Grille, 500 Crescent Court, Ste 135 (on Maple St.), Dallas, TX, 75201

INDICATION

AYVAKIT is indicated for the treatment of adult patients with Advanced SM (AdvSM) including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

Limitations of Use: AYVAKIT (avapritinib) is not recommended for the treatment of patients with AdvSM with platelet counts of <50 x 10^9/L.

IMPORTANT SAFETY INFORMATION

There are no contraindications for AYVAKIT.

Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. Overall, ICH (eg, subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT. In AdvSM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts ≥50 x 10^9/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. Monitor patients closely for risk of ICH including those with thrombocytopenia, vascular aneurysm or a history of ICH or cerebrovascular accident within the prior year. Permanently discontinue AYVAKIT if ICH of any grade occurs. A platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in AdvSM patients with platelet counts <50 x 10^9/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 10^9/L by treatment interruption or dose reduction.

Please see additional Important Safety Information throughout, and click here to see the full Prescribing Information for AYVAKIT.

You may register for this program by calling or texting Daniele Lafond at (214) 998-4848 or emailing dlafond@blueprintmedicines.com.

Information for virtual programs only: Zoom link will be provided following registration.

Information for in-person programs only: By accepting our invitation to attend this event, you confirm that: (a) neither you nor those in your household are experiencing COVID-19 symptoms or are in quarantine; (b) within the past 14 days you have not been diagnosed with, suspected to have, or exposed to, COVID-19; (c) you will fully comply with all requested COVID-19 and contact tracing protocols related to the event; (d) even with the protocols, participation in the event presents a risk of exposure to COVID-19; and (e) you will not participate in the event in person if you are unable to re-confirm all of the above as of the day of the event.

Blueprint Medicines is committed to complying with all applicable laws and regulations and adhering to the highest standards in its interactions with healthcare professionals. In accordance with the PhRMA Code, Blueprint Medicines will not pay for or provide alcohol in connection with speaker programs; and we are unable to accommodate spouses or guests at this event. This invitation is nontransferable and is for relevant healthcare professionals only. In order to ensure accurate transparency reporting of meals, Blueprint Medicines requires program attendees to sign in upon arrival. Subject to all applicable federal and/or state regulations, Blueprint Medicines will disclose information related to meals provided to you. In most cases, this information will be made public. Attendees may opt out of the meal by indicating on their RSVP. Minnesota, Vermont, the Department of Defense and the Department of Veteran Affairs have regulations or policies that prohibit the receipt of meals at company sponsored events. You are accountable for understanding such restrictions and complying with them. Blueprint Medicines may restrict your participation in this program.

For more information on AYVAKIT, visit AYVAKIT.com/hcp

IMPORTANT SAFETY INFORMATION (continued)

Cognitive adverse reactions can occur in patients receiving AYVAKIT. Cognitive adverse reactions occurred in 39% of 749 patients and in 28% of 148 SM patients (3% were Grade >3). Memory impairment occurred in 16% of patients; all events were Grade 1 or 2. Cognitive disorder occurred in 10% of patients; <1% of these events were Grade 3. Confusional state occurred in 6% of patients; <1% of these events were Grade 3. Other events occurred in <2% of patients. Depending on the severity, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue.

AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose.

The most common adverse reactions (≥20%) at all doses were edema, diarrhea, nausea, and fatigue/asthenia.

Please see additional Important Safety Information throughout, and click here to see the full Prescribing Information for AYVAKIT.

AYVAKIT® avapritinib | tablets

IMPORTANT SAFETY INFORMATION (continued)

Avoid coadministration of AYVAKIT with strong and moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong and moderate CYP3A inducers.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or **www.fda.gov/medwatch**.

Please click here to see the full Prescribing Information for AYVAKIT.

References: 1. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; June 2021.

blueprint™ MEDICINES